AVGO vs LLY
AVGO: Broadcom provides the essential semiconductor hardware and mission-critical software infrastructure that powers the world's most complex data centers, cloud networks, and enterprise IT systems. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | AVGO | LLY | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $420.57 | $1,191.94 | |
| Market cap as of 2026-08-08 | $2.00T | $1.12T | |
| P/E as of 2026-08-08 | 68.96 | 41.40 | LLY lower |
| PEG as of 2026-08-08 | 1.23 | 1.48 | AVGO lower |
| Net margin as of 2026-08-08 | +38.9% | +33.5% | AVGO higher |
| Gross margin as of 2026-08-08 | +68.3% | +83.4% | LLY higher |
| Operating margin as of 2026-08-08 | +43.4% | +42.2% | AVGO higher |
| ROE as of 2026-08-08 | +36.4% | +92.6% | LLY higher |
| ROA as of 2026-08-08 | +17.1% | +22.0% | LLY higher |
| Debt / equity as of 2026-08-08 | 0.74 | 1.62 | AVGO lower |
| Revenue growth (YoY) as of 2026-08-08 | +32.3% | +49.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +24.4% | +31.7% | LLY higher |
| Dividend yield as of 2026-08-08 | +0.6% | +0.6% | AVGO higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | LLY higher |
| Beta as of 2026-08-08 | 1.48 | 0.45 | |
| 1-year return as of 2026-08-06 close | +39.4% | +59.7% | LLY higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.